Form 4: Crinetics Pharmaceuticals Officer Sells Shares Under 10b5-1 Plan

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock at an average price of $48.55 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 10, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock.
• The sale was executed automatically under a Rule 10b5-1 trading plan previously adopted by Betz.
• The shares were sold in open market transactions at a volume-weighted average price of $48.55 per share.
• The price range for the sales on that day was between $48.46 and $48.63.
• Following the transaction, Betz still beneficially owns 78,611 shares of Crinetics Pharmaceuticals, including 968 shares acquired through the Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares sold.

Key Dates